Biopure Appoints New Independent Auditor

CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today that it has engaged Vitale, Caturano & Company,
Ltd as its independent auditor.
The audit committee of Biopure's board of directors made its selection
after a review of audit firms that had expertise with public clients of
Biopure's size and requirements.
Based in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. is a
large, regional registered public accounting firm. Vitale, Caturano & Company
replaces Ernst & Young, LLP.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the treatment
of surgical patients who are acutely anemic. Biopure's veterinary product
Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only
oxygen therapeutic approved for marketing by both the U.S. Food and Drug
Administration and the European Commission, is indicated for the treatment of
anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin
since 1998.

Contact: Tiana Gorham
Biopure Corporation
(617) 234-6826
IR@biopure.com

SOURCE Biopure Corporation

Tiana Gorham of Biopure Corporation, +1-617-234-6826, IR@biopure.com